Shares of US neurogenetic focused biotech Voyager Therapeutics (Nasdaq: VYGR) shot up 30% to $10.86 today, after it announced a capsid license agreement and strategic collaboration with Novartis (NOVN: VX) to advance novel potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA).
Voyager will provide the Swiss pharma giant with a target-exclusive license to access Voyager’s TRACER capsids and other intellectual property for the respective diseases, and Voyager and Novartis will collaborate to advance a preclinical gene therapy candidate for HD.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze